PXD013431

PXD013431 is an original dataset announced via ProteomeXchange.

Title	In-depth proteomic analysis for discovery of response prediction markers in breast cancer chemotherpy using needle biopsy FFPE tissue
Description	Breast cancer is the most frequently diagnosed female cancer accounting for 23 % of the total cases and the second leading cause of cancer mortality in the world, particularly in western countries. Since GEPARDUO trial reported the therapeutic benefit of combined doxorubicin and cyclophosphamide regimen in sequential administration with docetaxel, the combination regimen has become a standard therapeutic strategy in neoadjuvant systemic therapy for patients with operable breast cancers regardless of an intrinsic subtype. Although approximately 70% of entire patients are currently receiving the chemotherapy regimen, pathologic complete response (pCR) rate is still low, ranging from 23% to 32.7% due to the high heterogeneity of breast cancers. Therefore, the need for a marker predictive of response to a particular cytotoxic regimen, especially before neoadjuvant chemotherapy, is becoming all the more necessary to optimize therapeutic efficacy and to avoid unnecessary complications caused by systemic therapy. In the study, here we generated the first high-coverage proteomic data for needle biopsy FFPE sample being characterized with identical clinical conditions including chemotherapeutic regimens and the stage classification.
HostingRepository	PRIDE
AnnounceDate	2024-10-22
AnnouncementXML	Submission_2024-10-22_05:25:45.451.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Dohyun Han
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	monohydroxylated residue
Instrument	Q Exactive

Revision	Datetime	Status	ChangeLog Entry
0	2019-04-09 08:18:20	ID requested
1	2021-09-08 08:15:31	announced
⏵ 2	2024-10-22 05:25:47	announced	2024-10-22: Updated project metadata.

Lee KM, Lee H, Han D, Moon WK, Kim K, Oh HJ, Choi J, Hwang EH, Kang SE, Im SA, Lee KH, Ryu HS, Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. Breast Cancer Res, 22(1):130(2020) [pubmed]

10.1186/s13058-020-01367-7;

submitter keyword: breast cancer,FFPE, label-free quantification, chemotherapy

Dohyun Han
contact affiliation	Proteomics core facility, Biomedical Research Institute, Seoul National University Hospital
contact email	hdh03@snu.ac.kr
lab head
Dohyun Han
contact affiliation	Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital
contact email	hdh03@snu.ac.kr
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013431

PRIDE project URI

• PRIDE
  1. PXD013431
     1. Label: PRIDE project
     2. Name: In-depth proteomic analysis for discovery of response prediction markers in breast cancer chemotherpy using needle biopsy FFPE tissue